Date: November 13, 2016


Chronic skin ulcers, consequence of diabetes and other pathological conditions, heavily compromise the patients’ life quality and represent a high and constantly growing cost for National Health Services. Autologous Platelet Rich Plasma (PRP), has been proposed to treat these lesions. The absence of guidelines for the PRP production and the need of a fresh preparation for each treatment lead us to develop a protocol for the production of an allogenic PRP based bioactive membrane (BAM), standardized for platelet concentration and growth factor release. This work compares BAM obtained starting from two different platelet concentrations. We did not observe a direct correlation between the amount of growth factors released by BAM in vitro and the initial platelet count. However, different release kinetics were noticed for different growth factors, suggesting that they were differently retained by the two BAM. The angiogenic potential of both BAM was determined by Luminex Angiogenesis Assay. The biological activity of the factors released by the two BAM was confirmed by cell proliferation and migration. A diabetic mouse chronic ulcer model was used to define the best PRP therapeutic dose in vivo. Both BAM induced wound healing by increasing the thickness of the regenerated epidermis and the vessel number. However, a too high platelet concentration resulted in a slowdown of the membrane resorption that interfered with the skin healing. Overall our results indicate that the BAM could represent a natural and effective wound healing tool for the treatment of skin ulcer.